Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer

British Journal of Cancer

Volumn 111, Issue 10, 2014, Pages 1965-1976

  Wang, X ^a,b   Zuo, D ^a   Chen, Y ^b   Li, W ^c   Liu, R ^a   He, Y ^b   Ren, L ^a   Zhou, L ^a   Deng, T ^a   Ying, G ^a   Ba, Y ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c Tianjin Chest Hospital   (China)

Author keywords

chemotherapy; colorectal cancer; HB EGF; syndecan 1

Indexed keywords

CISPLATIN; FLUOROURACIL; GELATINASE B; HEPARANASE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IRINOTECAN; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXALIPLATIN; PACLITAXEL; SYNDECAN 1; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MMP7 PROTEIN, HUMAN; PLATINUM COMPLEX; SMALL INTERFERING RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL MEMBRANE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; CELL PROLIFERATION; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CAMPTOTHECIN; CASE-CONTROL STUDIES; CELL PROLIFERATION; CISPLATIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 7; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SYNDECAN-1; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84922482051     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.493     Document Type: Article

References (42)

1. Andrian E, Grenier D, Rouabhia M (2006) Porphyromonas gingivalis gingipains mediate the shedding of syndecan-1 from the surface of gingival epithelial cells. Oral Microbiol Immunol 21: 123-128
2. Anegawa G, Kawanaka H, Yoshida D, Konishi K, Yamaguchi S, Kinjo N, Taketomi A, Hashizume M, Shimokawa H, Maehara Y (2008) Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis. Hepatology 47: 966-977
3. Anttonen A, Leppa S, Heikkila P, Grenman R, Joensuu H (2006) Effect of treatment of larynx and hypopharynx carcinomas on serum syndecan-1 concentrations. J Cancer Res Clin Oncol 132: 451-457
4. Anttonen A, Leppa S, Ruotsalainen T, Alfthan H, Mattson K, Joensuu H (2003) Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer 41: 171-177
5. Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L, Gattegno L (2006) The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 16: 488-501
6. Chen P, Abacherli LE, Nadler ST, Wang Y, Li Q, Parks WC (2009) MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting alpha(2)beta(1) integrin activation. PLoS ONE 4: e6565
7. Chen SJ, Luan J, Zhang HS, Ruan CP, Xu XY, Li QQ, Wang NH (2012) EGFR-mediated G1/S transition contributes to the multidrug resistance in breast cancer cells. Mol Biol Rep 39: 5465-5471
8. Clarke PA, Dickson JH, Harris JC, Grabowska A, Watson SA (2006) Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res 66: 3504-3512
9. Ding K, Lopez-Burks M, Sanchez-Duran JA, Korc M, Lander AD (2005) Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol 171: 729-738
10. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, Sato H (2003) Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278: 40764-40770
11. Fitzgerald ML, Wang Z, Park PW, Murphy G, Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148: 811-824
12. Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki T, Saitoh Y, Kohgo Y (2001) Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 92: 1074-1081
13. Georges S, Heymann D, Padrines M (2012) Modulatory effects of proteoglycans on proteinase activities. Methods Mol Biol 836: 307-322
14. Gotte M (2003) Syndecans in inflammation. FASEB J 17: 575-591
15. Hashimoto Y, Skacel M, Adams JC (2008) Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors. BMC Cancer 8: 185
16. Hayashida K, Stahl PD, Park PW (2008) Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5. J Biol Chem 283: 35435-35444
17. Higashiyama S, Abraham JA, Klagsbrun M (1993) Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 122: 933-940
18. Ibrahim SA, Hassan H, Vilardo L, Kumar SK, Kumar AV, Kelsch R, Schneider C, Kiesel L, Eich HT, Zucchi I, Reinbold R, Greve B, Gotte M (2013) Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS ONE 8: e85737
19. Joensuu H, Anttonen A, Eriksson M, Makitaro R, Alfthan H, Kinnula V, Leppa S (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62: 5210-5217
20. Kim M, Murakami A, Ohigashi H (2007) Modifying effects of dietary factors on (-)-epigallocatechin-3-gallate-induced pro-matrix metalloproteinase-7 production in HT-29 human colorectal cancer cells. Biosci Biotechnol Biochem 71: 2442-2450
21. Kobayashi H, Higashiyama M, Minamigawa K, Tanisaka K, Takano T, Yokouchi H, Kodama K, Hata T (2001) Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification. Jpn J Cancer Res 92: 203-210
22. Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, Yasutomi M, Hanatani Y, Kotake K, Kubota T (1997) An in vitro chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. Int J Oncol 11: 449-455
23. Li Q, Park PW, Wilson CL, Parks WC (2002) Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111: 635-646
24. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, Moehler T, Rossi JF, Reme T, Goldschmidt H, Klein B (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109: 4914-4923
25. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279
26. Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, Pohlenz HD, Thierauch KH, Sommer A (2004) Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer 40: 1373-1382
27. Mythreye K, Blobe GC (2009) Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cell Signal 21: 1548-1558
28. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, Kelsch R, Fischgrabe J, Smollich M, Rossi LH, Sibrowski W, Wulfing P, Kiesel L, Yip GW, Gotte M (2009) Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30: 397-407
29. Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T, Kishine K, Ochi T, Okubo S, Futagawa S, Mashiko S, Nagaoka I (2012) Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test. Oncol Lett 4: 621-624
30. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G (2013) Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13: 49
31. Pruessmeyer J, Martin C, Hess FM, Schwarz N, Schmidt S, Kogel T, Hoettecke N, Schmidt B, Sechi A, Uhlig S, Ludwig A (2010) A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J Biol Chem 285: 555-564
32. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC, Sanderson RD (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115: 2449-2457
33. Ramani VC, Sanderson RD (2014) Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse. Matrix Biol 35: 215-222
34. Reiland J, Ott VL, Lebakken CS, Yeaman C, McCarthy J, Rapraeger AC (1996) Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1. Biochem J 319(Pt 1): 39-47
35. Su G, Blaine SA, Qiao D, Friedl A (2008) Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res 68: 9558-9565
36. Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H, Noguchi S (2002) Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer 98: 450-455
37. Teng YH, Aquino RS, Park PW (2012) Molecular functions of syndecan-1 in disease. Matrix Biol 31: 3-16
38. Wang X, Chen Y, Song Y, Zhang S, Xie X (2011) Activated Syndecan-1 shedding contributes to mice colitis induced by dextran sulfate sodium. Dig Dis Sci 56: 1047-1056
39. Wang Z, Gotte M, Bernfield M, Reizes O (2005) Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site. Biochemistry 44: 12355-12361
40. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy Jr. JD, Sawyer J, Li JP, Zcharia E, Vlodavsky I, Sanderson RD (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282: 13326-13333
41. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100: 610-617
42. Zhang S, Qing Q, Wang Q, Xu J, Zhi F, Park PW, Zhang Y, Chen Y (2013) Syndecan-1 and heparanase: potential markers for activity evaluation and differential diagnosis of Crohn's disease. Inflamm Bowel Dis 19: 1025-1033